Navigation Links
Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics' Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
Date:12/10/2007

- Company Plans to Initiate Phase IIa Study of NGX426 in Acute Migraine in

First Half of 2008 -

LA JOLLA, Calif., Dec. 10 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today reported pharmacokinetic data obtained in a Phase I maximum tolerated dose clinical trial of NGX426, the oral prodrug of tezampanel, show that the area under the curve (AUC), which represents the total amount of drug absorbed by the body, of a single, 80 mg, oral dose of NGX426 is comparable to the AUC of a single, 40 mg, subcutaneous dose of tezampanel.

With the recently demonstrated efficacy of 40 mg of tezampanel in a Phase IIb clinical trial in acute migraine, the comparable AUCs suggest that NGX426 also may be effective in treating acute migraine headache. TorreyPines Therapeutics plans to initiate a Phase IIa study of NGX426 in acute migraine in the first half of 2008.

"These findings with the oral form of tezampanel are very encouraging, especially when looked at in conjunction with the data from our evaluation of the subcutaneous form," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "These data fully support the continued development of NGX426, which, as an oral prodrug, can provide an additional route of administration for tezampanel to acute migraine sufferers."

Initiated earlier this year, this double-blind, placebo-controlled trial enrolled normal healthy adult volunteers in sequential, dose-escalating cohorts. The Phase I data show that single, oral doses of NGX426 from 40 mg to 90 mg are safe and well-tolerated. TorreyPines Therapeutics is amending the Phase I clinical trial protocol to extend the dosing range beyond 90 mg to identify the maximum tolerated dose.

Tezampanel is the first AMPA/kainate antagonist to be studied in a clinical trial for acute migraine. Both tezampanel and the oral prodrug NGX426 represent a novel, non-opiod, non-vascular and non-serotonergic approach to treating multiple pain conditions, including migraine. Tezampanel and NGX426 are antagonists of a subgroup of glutamate receptors referred to as AMPA and kainate. These receptors are found in areas of the central and peripheral nervous system that are important for the transmission of pain. During a migraine attack, levels of glutamate increase and activate these receptors, facilitating the transmission of pain impulses. Tezampanel, by blocking the binding of glutamate to these receptors, is believed to inhibit the transmission of pain signals that lead to migraine headaches.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include statements regarding the potential for tezampanel as a treatment for migraine, the potential for NGX426 as a treatment for migraine, the potential for tezampanel to offer a unique approach to the management of pain, the potential for NGX426 to offer a unique approach to the management of pain and the potential timing, development and initiation of Phase II clinical trials of NGX426. Such statements are subject to numerous risks, and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory approval and commercialization, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether the results of the Phase I trial are predictive of results in subsequent trials of NGX426, whether the areas under the curve for tezampanel and NGX426 are meaningful indicators of the efficacy of NGX426, whether further testing of tezampanel and NGX426 will result in data sufficient to support regulatory approval, whether AMPA/kainate antagonists will prove to be safe and effective treatments for migraine and other pain conditions, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support an NDA filing, will be approved by the FDA or its equivalent, or if approved, will prove competitive in the market; or whether the necessary financing to support its drug development programs will be available. Actual results may differ materially from the above forward-looking statements due to a number of other important factors. These and other risks which may impact management's expectations are described in greater detail in the TorreyPines Therapeutics annual report on Form 10-K for the year ended Dec. 31, 2006, as well as TorreyPines Therapeutics' subsequent filings with the Securities and Exchange Commission. TorreyPines Therapeutics undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Company Contact: Media Contact:

Ev Graham David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x118 212-845-4271

egraham@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact: Investor Contact:

Rhonda Chiger John Baldissera

Rx Communications BPC Financial Marketing

917-322-2569 800-368-1217

rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
3. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
4. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
5. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
6. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... HOUSTON , 8. Februar 2016 /PRNewswire/ ... veröffentlichte heute eine Infografik mit dem Titel ... ganzen Welt), mit der der Krankheit gegenüber ... die dazu ermutigen soll, Medikamentenresistenz bei Epilepsie ... der allgemeinen Diskussion zu machen. Mithilfe der ...
(Date:2/5/2016)... Feb. 5, 2016  ivWatch, a medical devices company, is ... Award granted by Governor Terry McAuliffe,s office. ivWatch ... February 25th at an event to be held at the ... award honors professionals and business that have made significant contributions ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... -- Aethlon Medical, Inc. (Nasdaq: AEMD ), today announced ... presenting at Source Capital Group,s 2016 Disruptive Growth & Healthcare ... 2:15 p.m. ET on Wednesday, February 10, 2016.  Mr. Joyce ... at 3:15 p.m. ET. http://www.aethlonmedical.com .  The webcast ... conclusion of the live event. The panel discussion will not ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with ... time to make a change in public health,” states Carole Baggerly, Director of ...
(Date:2/8/2016)... Las Vegas, NV (PRWEB) , ... February 08, 2016 , ... ... transformation on February 9th, 10th and 11th, 2016 in honor of his birthday on ... relationships and true happiness. Mahendra Trivedi is known by over 250,000 people from ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... Women's Excellence ... National Wear Red Day. National Wear Red Day is the first Friday each ... Heart disease and stroke cause 1 in 3 deaths among women each year – ...
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is proud ... . This event brings together top non-profit leaders, ultimate organizations, and coaches from around ... Valerio Iani, Bay Area Disc Program Director of Youth and Education, describes this year ...
(Date:2/5/2016)... ... 2016 , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran the Miami ... in 2003. This year, he ran all 26.2 miles with a green 25-pound ShelterBox ... Miami Heat. , This Sunday, while many are watching the Superbowl, Steven Tonkinson will ...
Breaking Medicine News(10 mins):